Overview
Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.
Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.
Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.